Your browser doesn't support javascript.
loading
mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >=16 Years in the United States, February to May 2021
Sara S Kim; Jessie R Chung; Edward A Belongia; Huong Q McLean; Jennifer P King; Mary Patricia Nowalk; Richard K Zimmerman; Goundappa K Balasubramani; Emily T Martin; Arnold S Monto; Lois E Lamerato; Manjusha Gaglani; Michael E Smith; Kayan M Dunnigan; Michael L Jackson; Lisa A Jackson; Mark W Tenforde; Jennifer R Verani; Miwako Kobayashi; Stephanie Schrag; Manish M Patel; Brendan Flannery.
Afiliación
  • Sara S Kim; Centers for Disease Control and Prevention
  • Jessie R Chung; Centers for Disease Control and Prevention
  • Edward A Belongia; Marshfield Clinic Research Institute
  • Huong Q McLean; Marshfield Clinic Research Institute
  • Jennifer P King; Marshfield Clinic Research Institute
  • Mary Patricia Nowalk; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Richard K Zimmerman; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Goundappa K Balasubramani; University of Pittsburgh Schools of the Health Sciences and University of Pittsburgh Medical Center
  • Emily T Martin; University of Michigan
  • Arnold S Monto; University of Michigan
  • Lois E Lamerato; Henry Ford Health System
  • Manjusha Gaglani; Baylor Scott and White Health and Texas A&M University College of Medicine
  • Michael E Smith; Baylor Scott and White Health
  • Kayan M Dunnigan; Baylor Scott and White Health
  • Michael L Jackson; Kaiser Permanente Washington Health Research Institute
  • Lisa A Jackson; Kaiser Permanente Washington Health Research Institute
  • Mark W Tenforde; Centers for Disease Control and Prevention
  • Jennifer R Verani; Centers for Disease Control and Prevention
  • Miwako Kobayashi; Centers for Disease Control and Prevention
  • Stephanie Schrag; Centers for Disease Control and Prevention
  • Manish M Patel; Centers for Disease Control and Prevention
  • Brendan Flannery; Centers for Disease Control and Prevention
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21260647
Artículo de revista
Un artículo publicado en revista científica está disponible y probablemente es basado en este preprint, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver artículo de revista
ABSTRACT
Evaluations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged [≥]16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI 83-95) for full vaccination and 75% (95% CI 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.
Licencia
cc_no
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo
Añadir a Mi BVS
Imprimir
XML
Buscar en Google
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies Idioma: En Año: 2021 Tipo del documento: Preprint